---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-051118"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:28:10.884274+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galecto receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

## Summary
- Nasdaq notified Galecto that common stock bid price closed below $1.00 for 30 consecutive business days.
- Company has until March 25, 2024 to regain compliance with Minimum Bid Price Requirement.
- If not cured, Galecto may qualify for a second 180-day period by transferring to Nasdaq Capital Market.
- Galecto may consider a reverse stock split to regain compliance, but no assurance of success.
- Common stock symbol GLTO continues trading on Nasdaq Global Select Market pending compliance.

## SEC filing metadata
- accession: 0000950170-23-051118
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017023051118/0000950170-23-051118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017023051118/glto-20230927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-051118
- JSON: https://secwatch.observer/filing/0000950170-23-051118.json
- Plain text: https://secwatch.observer/filing/0000950170-23-051118.txt

## Key facts
- Listing & Compliance Notices
  Damora Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: September 27, 2023, Galecto, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000095017023051118/0000950170-23-051118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.